The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Key advances shaping frontline treatment for AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the frontline treatment landscape for acute myeloid leukemia (AML), highlighting ongoing studies exploring combinations of menin inhibitors, hypomethylating agents, and targeted therapies, as well as the potential for oral therapies in the future. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, there’s lots of moving pieces in this area. We have multiple upfront induction studies, particularly looking at combinations with menin inhibitors. We have a series of upfront trials looking at the combination of hypomethylating agents and venetoclax plus targeted agents like FLT3 inhibitors, menin inhibitors, antibody drug conjugates. At the same time, there is a movement afoot to compare more intensive versus less intensive regimens for younger fit patients who have traditionally been candidates for intensive therapies...
Well, there’s lots of moving pieces in this area. We have multiple upfront induction studies, particularly looking at combinations with menin inhibitors. We have a series of upfront trials looking at the combination of hypomethylating agents and venetoclax plus targeted agents like FLT3 inhibitors, menin inhibitors, antibody drug conjugates. At the same time, there is a movement afoot to compare more intensive versus less intensive regimens for younger fit patients who have traditionally been candidates for intensive therapies. Perhaps they would tolerate less intensive therapies better and maintain some degree of activity and efficacy. So there are many different moving parts. And the good news is that overall, we appear to be increasing our options for patients with AML. And over time, perhaps we may be able to offer oral therapies because now we have an oral hypomethylating agent available. So I think it’s an exciting time and as it will play out over the course of the next five years we should be able to tell how things will be.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
